Capecitabine/cyclophosphamide combination therapy for patients with metastatic breast cancer- a prospective cohort study

Capecitabine/cyclophosphamide combination therapy for patients with metastatic breast cancer- a prospective cohort study - KBC-SG0901

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044444

Enrollment

Registered

2021-06-05

Start date

2009-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Inoperable advanced or recurrent breast cancer 2)Negative HER2 status (0 or 1+ by immunohistochemistry or negative by FISH) 3)Performance status of 0, 1, or 2 4)Adequate bone marrow reserve, hepatic, renal functions, and normal cardiac function 5)Written informed consent is required to obtain from each patient at each participating institution

Exclusion criteria

Exclusion criteria: 1)Pregnant or breast feeding 2)Documented history of serious hypersensitivity reaction on the medical drugs 3)Patients who have experienced prior chemotherapy with capecitabine 4)With metastasis to the central nervous system 5)Serious underlying medical illness with heart, gastrointestinal tract, or infection

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression free time, overall survival, adverse event.	—

Countries

Japan

Contacts

Public ContactKazuo Tamura

Kyushu Breast Cancer Study Group Office

kbc@chotsg.com092-406-4166

Outcome results